BDX — Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $5.3 billion, up 0.4% year-over-year.
• New BDX Revenue Growth: 2.5%, with broad-based growth across key markets.
• Adjusted Gross Margin: 53.4%, slightly down 140 basis points year-over-year due to tariffs.
• Adjusted EPS: $2.91, down 15.2% year-over-year, but exceeded expectations.
• Free Cash Flow: $548 million, with a conversion rate of 66%, up from 59% in the prior year.
• Shareholder Returns: Approximately $550 million returned, including $250 million in share buybacks.

2. Strategic Updates and Business Highlights

• Segment Reorganization: Transitioned to a new segment structure including Medical Essentials, Connected Care, Biopharma Systems, Interventional, and Life Sciences.
• Life Sciences Transaction: Closed a Reverse Morris Trust transaction with Waters, receiving a $4 billion cash distribution, with plans to allocate $2 billion for share repurchases and $2 billion for debt reduction.
• Growth Platforms: Strong performance in biologic drug delivery, PureWick, advanced tissue regeneration, and pharmacy automation, with double-digit growth in several areas.
• Operational Excellence: Achieved 8% productivity improvements and significant progress on a $200 million cost-out program.

3. Forward Guidance and Outlook

• Fiscal 2026 Revenue Growth: Expected low single-digit growth for New BDX, with Q2 revenue growth projected at approximately 2%.
• Adjusted EPS Guidance: Estimated range of $12.35 to $12.65, reflecting about 6% growth at the midpoint.
• Margin Expectations: Anticipated adjusted operating margin of about 25%, inclusive of tariff impacts.

4. Challenges and Points of Concern

• Headwinds:
  • Alaris: Continued challenges due to market dynamics and a tough comparison to prior year; expected to remain a headwind in 2026.
  • Vaccines: Lower demand impacting Biopharma Systems, particularly in China.
  • China Market Dynamics: Ongoing challenges due to volume-based procurement (VBP) impacting pricing and revenue.
• Tariff Impact: Tariffs negatively affected gross and operating margins, contributing to a decline in adjusted EPS.

5. Notable Q&A Insights

• Market Dynamics: Management expressed confidence in the core growth drivers and emphasized that the fundamentals of 90% of the portfolio remain strong despite known headwinds.
• Alaris Performance: While Alaris is expected to be a headwind, management noted strong competitive momentum and share gains.
• Innovation Pipeline: Increased focus on accelerating R&D timelines and new product launches, with expectations for significant contributions to growth in the coming years.
• Sales Force Expansion: Investments in expanding the sales force and enhancing commercial capabilities are expected to drive future growth.
• CFO Search: Ongoing search for a new CFO, with a focus on continuity and financial discipline during this transitional phase.

Overall, BDX reported solid Q1 results with strategic initiatives aimed at enhancing growth, despite facing specific challenges in certain segments and markets. The company remains optimistic about its future trajectory and operational execution.